Dr Jacqeline Barry: key facts
- Kind of voice
- Academic
- Role
- Chief Clinical Officer, Cell and Gene Therapy Catapult
- Quoted on
- Rare diseases
- Press citations held
- 2
- Most recently quoted
- 30 Sept 2026
“Advancing regulatory approaches for rare diseases is essential to ensure that patients with the greatest unmet need can access innovative treatments without unnecessary delay.”
What Dr Jacqeline Barry has said
“Through this initiative, the MHRA aims to create flexible, science-led regulatory pathways that speed up clinical trials and product approvals for rare disease therapies, while upholding the highest standards of safety, efficacy, and quality.”
Chief Clinical Officer at the Cell and Gene Therapy Catapult · Rare diseases · 30 Sept 2026 · MHRA set to overhaul the UK’s rare disease drug regulatory pathway ↗
Where Dr Jacqeline Barry has been quoted
- Major change for rare disease treatments on way, signals MHRAgov.uk · 30 Sept 2026
- MHRA set to overhaul the UK’s rare disease drug regulatory pathwayeuropeanpharmaceuticalreview.com · 30 Sept 2026
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 30 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.